Jim Roach – författare

"This is truly an outstanding book. [It] brings together all of the latest research in clinical trials methodology and how it can be applied to drug development…. Chang et al provide applications to industry-supported trials. This will allow statisticians in the industry community to take these methods seriously." Jay Herson, Johns Hopkins University

The pharmaceutical industry''s approach to drug discovery and development has rapidly transformed in the last decade from the more traditional Research and Development (R & D) approach to a more innovative approach in which strategies are employed to compress and optimize the clinical development plan and associated timelines. However, these strategies are generally being considered on an individual trial basis and not as part of a fully integrated overall development program. Such optimization at the trial level is somewhat near-sighted and does not ensure cost, time, or development efficiency of the overall program. This book seeks to address this imbalance by establishing a statistical framework for overall/global clinical development optimization and providing tactics and techniques to support such optimization, including clinical trial simulations.

It is important for statisticians to possess a deep knowledge of the drug development process beyond statistical considerations. For these reasons, this book incorporates both statistical and "clinical/medical" perspectives.

"This is truly an outstanding book. [It] brings together all of the latest research in clinical trials methodology and how it can be applied to drug development…. Chang et al provide applications to industry-supported trials. This will allow statisticians in the industry community to take these methods seriously." Jay Herson, Johns Hopkins University

The pharmaceutical industry''s approach to drug discovery and development has rapidly transformed in the last decade from the more traditional Research and Development (R & D) approach to a more innovative approach in which strategies are employed to compress and optimize the clinical development plan and associated timelines. However, these strategies are generally being considered on an individual trial basis and not as part of a fully integrated overall development program. Such optimization at the trial level is somewhat near-sighted and does not ensure cost, time, or development efficiency of the overall program. This book seeks to address this imbalance by establishing a statistical framework for overall/global clinical development optimization and providing tactics and techniques to support such optimization, including clinical trial simulations.

It is important for statisticians to possess a deep knowledge of the drug development process beyond statistical considerations. For these reasons, this book incorporates both statistical and "clinical/medical" perspectives.

Across the world there is growing awareness of the importance of innovation and knowledge transfer.  Innovation in the sense of generating new knowledge and making better use of existing knowledge, coupled with knowledge transfer and sharing paradigms, have never been more relevant to the universities, industry, commerce and the third sector.  This volume represents the proceedings of the Innovation through Knowledge Transfer 2012 Conference which formed an excellent opportunity to disseminate, share and discuss the impact of innovation, knowledge sharing, enterprise and entrepreneurship.  The volume contains papers presented at a Workshop on ‘The Meta Transfer of Knowledge: Challenges in the Transfer of Knowledge in Industry’, others from thematic sessions on ‘Next-Practice in University Based Open Innovation’,  ‘Social Innovation and Related Paradigms’, ‘Engagement with Industry and Commerce’ and ‘Knowledge Exchange’.  All papers were thoroughly reviewed by referees knowledgeable in practical and theoretical aspects of the subject.